A previous study reported that the use of sulphonylureas before and during the acute phase of cerebral ischaemia might have a significant, clinically meaningful effect on stroke outcomes in patients with T2D.48 However, the improvement was not observed in the subgroup of patients with LS, which might be explained by the small sample size of lacunar infarcts, especially in the treatment group.48 Although we did not find a significant proxy in the SLC5A2 locus, recent evidence suggests that SGLT2 inhibition might reduce LS risk and WMH volumes.49 This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.